Literature DB >> 18295504

miRNAs: Little known mediators of oncogenesis.

Andrei L Gartel1, Eugene S Kandel.   

Abstract

Cancer progression is mediated by overexpression of oncogenes and downregulation or loss of tumor suppressors. Proteins, which were traditionally categorized into these groups, have been recently joined by a species of RNA molecules known as microRNAs (miRNAs). miRNAs belong to a class of approximately 22-nt-long non-coding RNAs found in eukaryotes that hinder gene expression by inducing degradation or inhibiting translation of select mRNAs. A growing number of miRNAs have been implicated in promoting or suppressing tumorigenesis in a variety of tissues. The supporting evidence ranges from suggestive expression profiling data to direct functional validation using methods of forward and reverse genetics. We discuss the nature of published results, as well as the merits and pitfalls of various approaches aimed at identification of cancer-related miRNAs and their mRNA targets.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295504     DOI: 10.1016/j.semcancer.2008.01.008

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  70 in total

1.  Functional genomics of tumor suppressor miR-196b in T-cell acute lymphoblastic leukemia.

Authors:  Suman Bhatia; Deepak Kaul; Neelam Varma
Journal:  Mol Cell Biochem       Date:  2010-10-06       Impact factor: 3.396

2.  Differential expression of miR-144* as a novel fecal-based diagnostic marker for colorectal cancer.

Authors:  Murugan Kalimutho; Giovanna Del Vecchio Blanco; Serena Di Cecilia; Pierpaolo Sileri; Micaela Cretella; Francesco Pallone; Giorgio Federici; Sergio Bernardini
Journal:  J Gastroenterol       Date:  2011-08-24       Impact factor: 7.527

3.  The evidence for a microRNA product of human DROSHA gene.

Authors:  Peter Mechtler; Sydney Johnson; Hannah Slabodkin; Amir B Cohanim; Leonid Brodsky; Eugene S Kandel
Journal:  RNA Biol       Date:  2017-09-05       Impact factor: 4.652

4.  Prognostic value of microRNA-20b expression level in patients with prostate cancer.

Authors:  Rongkui Zhang; Fuwei Li; Yuchong Wang; Ming Yao; Changliang Chi
Journal:  Histol Histopathol       Date:  2020-04-14       Impact factor: 2.303

5.  A systematic analysis of miRNA transcriptome in Marek's disease virus-induced lymphoma reveals novel and differentially expressed miRNAs.

Authors:  Ling Lian; Lujiang Qu; Yanmei Chen; Susan J Lamont; Ning Yang
Journal:  PLoS One       Date:  2012-11-30       Impact factor: 3.240

6.  The noncoding RNA, miR-126, suppresses the growth of neoplastic cells by targeting phosphatidylinositol 3-kinase signaling and is frequently lost in colon cancers.

Authors:  Chunguang Guo; Jerome F Sah; Lydia Beard; James K V Willson; Sanford D Markowitz; Kishore Guda
Journal:  Genes Chromosomes Cancer       Date:  2008-11       Impact factor: 5.006

7.  Integrative genome analysis reveals an oncomir/oncogene cluster regulating glioblastoma survivorship.

Authors:  Hyunsoo Kim; Wei Huang; Xiuli Jiang; Brenton Pennicooke; Peter J Park; Mark D Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-13       Impact factor: 11.205

Review 8.  RNAi-based strategies for cyclooxygenase-2 inhibition in cancer.

Authors:  Antonio Strillacci; Cristiana Griffoni; Maria Chiara Valerii; Giorgia Lazzarini; Vittorio Tomasi; Enzo Spisni
Journal:  J Biomed Biotechnol       Date:  2010-06-13

9.  MicroRNA miR-146a and further oncogenesis-related cellular microRNAs are dysregulated in HTLV-1-transformed T lymphocytes.

Authors:  Klemens Pichler; Grit Schneider; Ralph Grassmann
Journal:  Retrovirology       Date:  2008-11-12       Impact factor: 4.602

10.  miRGen 2.0: a database of microRNA genomic information and regulation.

Authors:  Panagiotis Alexiou; Thanasis Vergoulis; Martin Gleditzsch; George Prekas; Theodore Dalamagas; Molly Megraw; Ivo Grosse; Timos Sellis; Artemis G Hatzigeorgiou
Journal:  Nucleic Acids Res       Date:  2009-10-22       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.